BMJ  2006;332:1115-1124 (13 May), doi:10.1136/bmj.38793.468449.AE (published 3 April 2006)

Research

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

¹ Center for Evidence-Based Medicine, University of Lisbon School of Medicine, Lisbon, Portugal, ² Department of Cardiology, Santa Maria University Hospital, Lisbon

Abstract

Objective To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention.

Design Systematic review and meta-analysis.

Data sources Cochrane, Medline, Embase, and reference lists up to April 2004.

Study selection Randomised, placebo controlled, double blind trials with a follow-up of at least three years that evaluated lipid lowering drug treatment in patients with and without diabetes mellitus.

Data extraction Two independent reviewers extracted data. The primary outcome was major coronary events defined as coronary heart disease death, non-fatal myocardial infarction, or myocardial revascularisation procedures.

Results Twelve studies were included. Lipid lowering drug treatment was found to be at least as effective in diabetic patients as in non-diabetic patients. In primary prevention, the risk reduction for major coronary events was 21% (95% confidence interval 11% to 30%; P < 0.0001) in diabetic patients and 23% (12% to 33%; P = 0.0003) in non-diabetic patients. In secondary prevention, the corresponding risk reductions were 21% (10% to 31%; P = 0.0005) and 23% (19% to 26%; P 0.00001). However, the absolute risk difference was three times higher in secondary prevention. When results were adjusted for baseline risk, diabetic patients benefited more in both primary and secondary prevention. Blood lipids were reduced to a similar degree in both groups.

Conclusions The evidence that lipid lowering drug treatment (especially statins) significantly reduce cardiovascular risk in diabetic and non-diabetic patients is strong and suggests that diabetic patients benefit more, in both primary and secondary prevention. Future research should define the threshold for treatment of these patients and the desired target lipid concentrations, especially for primary prevention.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

Giovanni F M Strippoli, Sankar D Navaneethan, David W Johnson, Vlado Perkovic, Fabio Pellegrini, Antonio Nicolucci, and Jonathan C Craig
BMJ 2008 336: 645-651. [Abstract] [Full Text] [PDF]

Prevention and early detection of vascular complications of diabetes

Sally M Marshall and Allan Flyvbjerg
BMJ 2006 333: 475-480. [Extract] [Full Text] [PDF]

Lipid lowering drugs in diabetes: Abstract was misleading

Mieke L van Driel and Pierre Chevalier
BMJ 2006 332: 1272. [Extract] [Full Text] [PDF]

Lipid lowering drugs in diabetes: Absolute risk reduction is what counts

L S Lewis
BMJ 2006 332: 1272. [Extract] [Full Text]

Lipid lowering drugs in diabetes: Lipid lowering has ophthalmic benefits

Hiten G Sheth, Sher Aslam, and Nigel Davies
BMJ 2006 332: 1272-1273. [Extract] [Full Text]

Diabetes and lipid lowering: where are we?

John P D Reckless
BMJ 2006 332: 1103-1104. [Extract] [Full Text] [PDF]

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

M R Law, N J Wald, and A R Rudnicka
BMJ 2003 326: 1423. [Abstract] [Full Text] [PDF]

Numbers needed to treat derived from meta-analysessometimes informative, usually misleading

Liam Smeeth, Andy Haines, and Shah Ebrahim
BMJ 1999 318: 1548-1551. [Extract] [Full Text] [PDF]

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

M R Law, N J Wald, and S G Thompson
BMJ 1994 308: 367-372. [Abstract] [Full Text]

This article has been cited by other articles:

• Norris, S. L., Kansagara, D., Bougatsos, C., Fu, R. (2008). Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 148: 855-868 [Abstract] [Full text]  
• Fujii, T., Onimaru, M., Yonemitsu, Y., Kuwano, H., Sueishi, K. (2008). Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression. Am. J. Physiol. Heart Circ. Physiol. 294: H2785-H2791 [Abstract] [Full text]  
• Strippoli, G. F M, Navaneethan, S. D, Johnson, D. W, Perkovic, V., Pellegrini, F., Nicolucci, A., Craig, J. C (2008). Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336: 645-651 [Abstract] [Full text]  
• Wienbergen, H., Senges, J., Gitt, A. K. (2008). Should We Prescribe Statin and Aspirin for Every Diabetic Patient?: Is it time for a polypill?. Diabetes Care 31: S222-S225 [Full text]  
• Stirban, A. O., Tschoepe, D. (2008). Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care 31: S226-S228 [Abstract] [Full text]  
• Werner, C., Kamani, C. H., Gensch, C., Bohm, M., Laufs, U. (2007). The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance. Diabetes 56: 2609-2615 [Abstract] [Full text]  
• Weymiller, A. J., Montori, V. M., Jones, L. A., Gafni, A., Guyatt, G. H., Bryant, S. C., Christianson, T. J. H., Mullan, R. J., Smith, S. A. (2007). Helping Patients With Type 2 Diabetes Mellitus Make Treatment Decisions: Statin Choice Randomized Trial. Arch Intern Med 167: 1076-1082 [Abstract] [Full text]  
• Laustsen, P. G., Russell, S. J., Cui, L., Entingh-Pearsall, A., Holzenberger, M., Liao, R., Kahn, C. R. (2007). Essential Role of Insulin and Insulin-Like Growth Factor 1 Receptor Signaling in Cardiac Development and Function. Mol. Cell. Biol. 27: 1649-1664 [Abstract] [Full text]  
• Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D'Agostino, R. B. Sr, Perez, A., Provost, J.-C., Haffner, S. M. (2006). Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial. JAMA 296: 2572-2581 [Abstract] [Full text]  
• Marshall, S. M, Flyvbjerg, A. (2006). Prevention and early detection of vascular complications of diabetes.. BMJ 333: 475-480 [Full text]  
• (2006). From the Library. Br. J. Ophthalmol. 90: 1214-1214 [Full text]  
• (2006). Statins for primary prevention in type 2 diabetes. DTB 44: 57-60 [Abstract] [Full text]  
• (2006). Aggressive Lipid Lowering Is Especially Helpful in Diabetics. JWatch Gastroenterology 2006: 7-7 [Full text]  
• (2006). Aggressive Lipid Lowering Is Especially Helpful in Diabetics. JWatch General 2006: 1-1 [Full text]  
• van Driel, M. L, Chevalier, P. (2006). Lipid lowering drugs in diabetes: abstract was misleading.. BMJ 332: 1272-1272 [Full text]  
• Lewis, L S (2006). Lipid lowering drugs in diabetes: absolute risk reduction is what counts.. BMJ 332: 1272-1272 [Full text]  
• Sheth, H. G, Aslam, S., Davies, N. (2006). Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits.. BMJ 332: 1272-1273 [Full text]  
• Reckless, J. P D (2006). Diabetes and lipid lowering: where are we?. BMJ 332: 1103-1104 [Full text]  

Rapid Responses:

Read all Rapid Responses

Limitations of Meta-analysis may cloud Primary Outcome Differences

Ameet Bakhai, et al.
bmj.com, 4 Apr 2006 [Full text]

Meta-analysis of lipid lowering treatment: abstract misleading?

Mieke L van Driel, et al.
bmj.com, 11 Apr 2006 [Full text]

Lipid Lowering Therapy in Diabetes – Ophthalmic Benefits

Hiten G Sheth, et al.
bmj.com, 14 May 2006 [Full text]

Benefits more ? Relatives and Absolutes...

L S Lewis
bmj.com, 15 May 2006 [Full text]

Determining the threshold for statin treatment in people with type 2 diabetes

Peter T. Donnan, et al.
bmj.com, 15 Jun 2006 [Full text]